BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the Roth 23 rd Annual Growth Stock Conference. The conference will take place March 13-16, 2011 in Dana Point, CA.

Stephen M. Simes, BioSante’s president & CEO, will speak Tuesday, March 15, 2011 at 10:30 am PT. He will provide an overview of the company, as well as an update on the LibiGel ® (testosterone gel) Phase III clinical development program. A live audio webcast of Mr. Simes’ remarks may be accessed at: http://www.wsw.com/webcast/roth24/bpax/. The webcast will be archived approximately three hours after the live event and will be available for 90 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.

Copyright Business Wire 2010